Phase 2 N=295 Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)
COVID-19
Primary: Disease Progression at Day 28 — 10; 6 Participants — p=0.787
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=103 A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
IgA Nephropathy · CKD Associated With Type 1 Diabetes · Focal Segmental Glomerulosclerosis
Primary: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 12 — 9.31; 8.00; 5.46; 7.83 mL/min/1.73 m^2 — p=<0.0001
Phase 2 N=106 Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
Acute Myocardial Infarction
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 28; 30; 31; 14 Participants
Phase 2 N=225 A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
Cystic Fibrosis
Primary: Parts A, B and C: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 0; 3; 1; 2 Participants
Phase 2 N=29 Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
Neuroendocrine Tumors · Carcinoid Tumors
Primary: Progression-free Survival (PFS) at One Year — 11 months
Phase 2 N=365 An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy
Epilepsy
Primary: Number of Participants With At Least One Treatment-Emergent Adverse Event (TEAE) — 336 Participants
Phase 2 N=263 Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
Cirrhosis · Portal Hypertension · Non-alcoholic Steatohepatitis
Primary: Mean Change in Hepatic Venous Pressure Gradient (HVPG) — -0.48; -0.81; -0.70; -0.18 mmHg
Phase 2 N=95 Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder
Alcohol Use Disorder
Primary: Drinks Per Drinking Day — 3.70; 3.60; 3.37; 3.99 drinks per drinking day — p=0.94
Phase 2 N=60 Resveratrol and Exercise to Treat Functional Limitations in Late Life
Aging
Primary: Walking Speed — -0.04; -0.03; 0.04 m/s
Phase 2 N=307 A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
Breast Cancer · Breast Carcinoma · Breast Tumors
Primary: Measurement of the Proliferation Marker Ki67 (% Positive Tumor Cells) — -2.2; -4.1 log fold change in Ki67
Phase 2 N=19 A Research Study to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102
Lumbosacral Radicular Pain
Primary: Change in Plasma Cortisol Concentrations From Baseline — 36.62; 0.64; 6.26; 29.77 nmol/L
Phase 2 N=49 Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin
Unresectable Intrahepatic Cholangiocarcinoma
Primary: Tumor Response (Overall Response = Complete Response + Partial Response + Progressive Disease + Stable Disease) — 24; 22 participants
Phase 2 N=54 Study in Subjects Undergoing Complete Abdominoplasty
Postsurgical Pain
Primary: Pain Intensity Scores at 96 Hours at Rest Using Numerical Rating Scale (NRS) — 2.8; 2.0; 3.0; 2.8 score on a scale — p=0.2912
Phase 2 N=24 MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Mesothelioma
Primary: Change in Ratio of Intratumoral Cytotoxic T Cells to Regulatory T Cells (CD8/Treg) — 8.6 no unit of ratios with same units(%) — p=0.109
Phase 2 N=42 Pembrolizumab and GM-CSF in Biliary Cancer
Biliary Cancer
Primary: Overall Response Rate (ORR) — 0.12 proportion of participants